The shift from conventional cytotoxic drugs to so called targeted drugs and immune modulators administered continuously and at maximum tolerated dose has changed the tolerability and toxicity profiles of anti-cancer drugs. The aim of this revision is to find ways on how to report adverse effects in order to improve the understanding of the toxicity and tolerability profiles of medicinal products.


Posted on the EMA website on 30 April 2015